[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aortic-valve-calcification\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aortic-valve-calcification":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100504659","mechanisms-of-disease-progression-in-aortic-stenosis---the-modas-study-100504659",false,"NCT05851209","Mechanisms Of Disease Progression in Aortic Stenosis - the MODAS Study","Evaluation of Immunologic and Image Morphologic Parameters to Predict Disease Progression in Patients With Moderate Aortic Valve Stenosis","Inclusion Criteria:\n\n* The patient has an acquired (tricuspid) moderate aortic valve stenosis, which is the reason for regular outpatient cardiological care.\n* The subject has been informed verbally and in writing about the study and has given written consent to participate in this study.\n* Age \\> 18 years\n\nExclusion Criteria:\n\n* The subject has contraindications for the performance of a magnetic resonance imaging or computed tomography (e.g., severe arrhythmias , contrast agent intolerance, a pacemaker, or severe renal insufficiency or severe renal insufficiency or claustrophobia).\n* Presence of only mild or already high-grade acquired tricuspid Aortic valve stenosis\n* Patient with bicuspid aortic valve\n* Inability to follow the instructions of study personnel\n* Lack of written informed consent","ALL","18 Years",{"count":19,"type":20},938,"ESTIMATED","OBSERVATIONAL","Biomarkers and mechanisms in the progression of aortic valve stenosis are sometimes not sufficiently understood. The current project will take into account image morphological and immunological aspects that predict the development of hemodynamically relevant aortic valve stenosis in order to identify high-risk patients and to develop further therapeutic options.",[24,25,26,27,28,29],"Aortic Stenosis","Imaging","Pathogenesis","Disease Progression","Aortic Valve Calcification","Genetics",[31,32,33,34,35,36,37],"severe aortic stenosis","disease progression","pathogenesis of degenerative aortic stenosis","early detection","Cardiovascular magnet resonance","Transthoracal echocardiography","computertomography","RECRUITING","2026-06-26",{"date":41,"type":42},"2026-06-30","ACTUAL",{"date":44,"type":42},"2023-07-01",{"date":46,"type":20},"2031-07",{"name":48,"class":49},"Heinrich-Heine University, Duesseldorf","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100632969","valvosoft-outcomes-registry-for-real-world-evidence-100632969","NCT07520591","Valvosoft Outcomes Registry for Real-World Evidence","Prospective Post-Market Clinical Follow-Up Registry to Assess the Long-term Safety and Effectiveness for the Treatment of Severe Symptomatic Aortic Valve Stenosis Using Valvosoft Non-Invasive Ultrasound Therapy","VALOR-PMCF","Inclusion Criteria:\n\n1. Suffering from calcific sSAS according to the definition presented in the current and applicable Guidelines for the management of valvular heart disease.\n2. Not recommended by the local heart team for immediate TAVR\u002FSAVR, or refusing such an intervention.\n3. Willing to provide a written informed consent prior to participating in this Registry.\n4. Able to comply with the follow up schedule or other Study requirements.\n\nExclusion Criteria:\n\n1. Prosthetic aortic valve;\n2. Chest deformity preventing optimal contact between Patient's chest and Valvosoft Applicator;\n3. Thoracic injured skin, presence of scar(s) and\u002For burn(s) on thorax that may be in contact or close proximity with Valvosoft Applicator;\n4. Pregnant or breastfeeding Patient.",{"count":59,"type":20},200,"The VALvosoft Outcomes Registry for Real-World Evidence (VALOR-PMCF) is a prospective, multicenter, single-arm post-market clinical follow-up (PMCF) registry designed to evaluate the long-term safety and effectiveness of the Valvosoft® non-invasive ultrasound therapy (NIUT) device in patients with severe symptomatic calcific aortic stenosis (sSAS).\n\nValvosoft® delivers focused, high-intensity, short-duration ultrasound pulses to the aortic valve via a trans-thoracic approach, inducing non-thermal mechanical softening of calcified valve tissue.\n\nThis registry will enroll up to 200 participants across approximately 20 clinical sites in Europe following CE marking. Participants will be followed from discharge through 12 months post-procedure to assess clinical outcomes, quality of life, echocardiographic parameters, and safety events in a real-world setting.",[62,63,28,64,65],"Aortic Valve Disease","Aortic Stenosis, Severe","Ultrasound Therapy","Heart Failure","NOT_YET_RECRUITING","2026-04-09",{"date":69,"type":42},"2026-04-14",{"date":71,"type":20},"2026-05-30",{"date":73,"type":20},"2028-06-30",{"name":75,"class":76},"Cardiawave SA","INDUSTRY",6,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100568992","valvular-assessment-of-new-generation-aortic-replacement-devices-100568992","NCT06688448","Valvular Assessment of New Generation Aortic Replacement Devices","Comparative Efficacy and Durability of Next-Generation Biological Aortic Prostheses.","VANGUARD","Inclusion Criteria:\n\n* Age: 18 to 65 years.\n* Eligible for surgical replacement of native valve or re-replacement of a prosthetic valve with a bioprosthetic valve in the aortic position.\n\nExclusion Criteria:\n\n* Indicated for mechanical prosthetic valve replacement.\n* Require surgical intervention in another heart valve or transcatheter valve therapy.","65 Years",{"count":59,"type":20},"INTERVENTIONAL",[90],"NA","The VANGUARD study is an open-label, prospective, randomized trial comparing the long-term outcomes of two advanced bioprosthetic aortic valves, Dafodil® and INSPIRIS Resilia®, in patients undergoing aortic valve replacement (AVR). This study aims to provide robust data on valve durability, safety, and hemodynamic performance, particularly in younger patients who may require multiple interventions over their lifetimes.",[93,28,94],"Aortic Regurgitation Disease","Bicuspid Aortic Valve Disease",[96,97,98,99,100],"aortic valve surgery","Dafodil®","Inspires Resilia®","bioprosthetic valves","aortic valve replacement","2025-01-09",{"date":103,"type":42},"2025-01-13",{"date":105,"type":42},"2024-12-01",{"date":107,"type":20},"2036-12-01",{"name":109,"class":49},"Instituto Dante Pazzanese de Cardiologia",1]